We’re excited to have partnered with Pall Biotech to publish two new posters.
- The first looks at leveraging biomass probes with chemically defined, serum-free media to optimize transfection cell density.
- The second demonstrates the optimization of the chemically defined media to be used for lentivirus production at scale with HEK293t cells.
Recent Advances of Chemical Definition of Cell Culture Media and Excipients for Virus and Viral Vector Manufacturing
Virus production is a critical step in cell and gene therapies and vaccine manufacture. Due to supply chain constraints, poor reproducibility, and safety concerns attributed to potential adventitious agents present in serum and serum-derived proteins, regulatory agencies have encouraged replacement of these components. Recombinant albumin and transferrin can successfully replace serum-derived proteins these applications.
Emergence of a Blood-Free rHSA
Blood-Free rHSA will add safety, consistency, and enhanced performance to your cell culturing processes.
Our new Featured Report explores the many benefits of albumin and the various challenges that serum-derived proteins can create. Recombinant human serum albumin (rHSA), and specifically InVitria’s Blood-Free rHSA, overcomes these challenges, enhances performance, and is preferred by regulatory agencies.
Learn How Exbumin Became the First FDA- and EMA-Approved Excipient in the New Cell Culture Dish Article
Cell Culture Dish summarizes Merck's IPEC webinar detailing the first-hand account of the complex process of regulatory agency drug product filing. The journey focuses on Merck's Ebola vaccine ERVEBO® and how it came to use Exbumin as an excipient.
NEW White Paper
Learn how recombinant transferrin enhances transient transfection and functional titer in viral vector production.
The global leader in the production of blood-free components, supplements, and media to facilitate the approval of life changing medicines.
InVitria’s portfolio of chemically defined blood-free products enables development and production of novel therapeutics without use of any blood-derived components.
Click on the application of interest to find out how our products set the new standards in biologics manufacturing.
InVitria offers a suite of recombinant protein products, each of which is completely free of animal or human components and produced in a scalable, non-mammalian recombinant expression system at an ISO9001:2015 certified facility in Kansas, USA.
InVitria is the leading brand of custom media formulations for gene therapy, cell therapy, vaccine & antibody production, and related culturing applications. Contact us to discuss your cell culture needs. Let us do the heavy lifting!
- Blood-Free & Chemically Defined
- High Performance
- Reliable Supply Chain
- Faster Time to Market
Select the cell line or an application of interest and discover more information relevant to your work.
- Decreased variability in cell culture media.
- Accelerated gene therapy research.
- Improved scalability & increased speed of gene therapy manufacturing.
- Reduced cost in time and resources for manufacturing.